Breaking Down Artivion: 4 Analysts Share Their Views

4 analysts have expressed a variety of opinions on Artivion AORT over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.5, a high estimate of $30.00, and a low estimate of $22.00. Marking an increase of 10.87%, the current average surpasses the previous average price target of $23.00.

Deciphering Analyst Ratings: An In-Depth Analysis

The perception of Artivion by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Artivion. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Artivion compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Artivion's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Artivion's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Artivion analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Artivion Better

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.

Financial Insights: Artivion

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Artivion's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 17.98%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Artivion's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.23% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Artivion's ROE excels beyond industry benchmarks, reaching -1.43%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Artivion's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.51%, the company showcases efficient use of assets and strong financial health.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.27, caution is advised due to increased financial risk.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.